Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-01-11
2005-01-11
Solola, Taofiq (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S491000
Reexamination Certificate
active
06841568
ABSTRACT:
This invention relates to compounds which are agonists of the progesterone receptor which have the general structure:wherein:R1, R2, R3, R4, R5and Q1are as defined herein, or a pharmaceutically acceptable salt thereof, as well as methods of using these compounds to induce contraception or treat progesterone-related carcinomas and adenocarcinomas.
REFERENCES:
patent: 3635964 (1972-01-01), Skorcz
patent: 3917592 (1975-11-01), Kobzina
patent: 4093730 (1978-06-01), Butti
patent: 4440785 (1984-04-01), Walsh
patent: 4617302 (1986-10-01), Robertson
patent: 4666913 (1987-05-01), Kuhla
patent: 4670566 (1987-06-01), Walsh
patent: 4721721 (1988-01-01), Kuhla
patent: 4822794 (1989-04-01), Spada
patent: 4831027 (1989-05-01), Narr
patent: 4853473 (1989-08-01), Fischer
patent: 4933336 (1990-06-01), Martin
patent: 5007952 (1991-04-01), Kume
patent: 5171851 (1992-12-01), Kim
patent: 5182282 (1993-01-01), Clemence et al.
patent: 5300655 (1994-04-01), Ehrgott et al.
patent: 5414088 (1995-05-01), von der Saal
patent: 5447928 (1995-09-01), Williams
patent: 5453516 (1995-09-01), Fischer
patent: 5475020 (1995-12-01), Johnson
patent: 5521166 (1996-05-01), Grubb
patent: 5552412 (1996-09-01), Cameron
patent: 5565483 (1996-10-01), Hewawasam et al.
patent: 5576330 (1996-11-01), Buzzetti et al.
patent: 5659046 (1997-08-01), Kameswaran
patent: 5681817 (1997-10-01), Hodgen
patent: 5688808 (1997-11-01), Jones
patent: 5688810 (1997-11-01), Jones
patent: 5693646 (1997-12-01), Jones
patent: 5693647 (1997-12-01), Jones
patent: 5696127 (1997-12-01), Jones
patent: 5696130 (1997-12-01), Jones
patent: 5696133 (1997-12-01), Jones
patent: 5719136 (1998-02-01), Chwalisz
patent: 5733902 (1998-03-01), Schneider
patent: 5808139 (1998-09-01), Pathirana
patent: 5874430 (1999-02-01), Christ
patent: 6077840 (2000-06-01), Kurihara
patent: 6153622 (2000-11-01), Cameron
patent: 6204286 (2001-03-01), Cameron
patent: 6306851 (2001-10-01), Santilli
patent: 6319912 (2001-11-01), Grubb
patent: 6329416 (2001-12-01), Grubb
patent: 6339098 (2002-01-01), Collins
patent: 6355648 (2002-03-01), Fensome et al.
patent: 6358947 (2002-03-01), Zhi
patent: 6358948 (2002-03-01), Zhang
patent: 6369056 (2002-04-01), Zhang
patent: 6380178 (2002-04-01), Grubb
patent: 6380235 (2002-04-01), Zhang
patent: 6391907 (2002-05-01), Fensome
patent: 6399593 (2002-06-01), Grubb
patent: 6407101 (2002-06-01), Collins
patent: 6417214 (2002-07-01), Ullrich
patent: 6423699 (2002-07-01), Grubb
patent: 6436929 (2002-08-01), Zhang
patent: 6441019 (2002-08-01), Santilli
patent: 6441193 (2002-08-01), Cameron
patent: 6444668 (2002-09-01), Grubb
patent: 6462032 (2002-10-01), Grubb
patent: 6498154 (2002-12-01), Grubb
patent: 6503939 (2003-01-01), Grubb
patent: 6509334 (2003-01-01), Zhang et al.
patent: 6521657 (2003-02-01), Fensome et al.
patent: 6544970 (2003-04-01), Grubb et al.
patent: 6566358 (2003-05-01), Zhang et al.
patent: 6583145 (2003-06-01), Fensome et al.
patent: 20010025051 (2001-09-01), Cameron
patent: 20020068735 (2002-06-01), Collinstead
patent: 20020086874 (2002-07-01), Fensome et al.
patent: 20020094983 (2002-07-01), Zhang et al.
patent: 20020111355 (2002-08-01), Zhang et al.
patent: 20020115853 (2002-08-01), Zhang et al.
patent: 20020151531 (2002-10-01), Grubb et al.
patent: 20030008909 (2003-01-01), Ullrich
patent: 20030045511 (2003-03-01), Grubb et al.
patent: 20030092711 (2003-05-01), Zhang et al.
patent: 3633861 (1988-04-01), None
patent: 4330234 (1995-03-01), None
patent: 4344463 (1995-06-01), None
patent: 022317 (1981-01-01), None
patent: 208510 (1987-01-01), None
patent: 311135 (1989-04-01), None
patent: 385850 (1990-09-01), None
patent: 483077 (1991-09-01), None
patent: 454330 (1991-10-01), None
patent: 535529 (1992-09-01), None
patent: 510235 (1992-10-01), None
patent: 947507 (1999-10-01), None
patent: 978279 (2000-02-01), None
patent: 63112584 (1988-05-01), None
patent: 2067576 (1996-10-01), None
patent: N2073671 (1997-02-01), None
patent: 95121739 (1998-02-01), None
patent: N96111002 (1998-09-01), None
patent: WO8603749 (1986-07-01), None
patent: WO9104974 (1991-04-01), None
patent: WO9106545 (1991-05-01), None
patent: WO9312085 (1993-06-01), None
patent: WO9414434 (1994-07-01), None
patent: WO9429272 (1994-12-01), None
patent: WO9511013 (1995-04-01), None
patent: WO9520389 (1995-08-01), None
patent: WO9520972 (1995-08-01), None
patent: WO9533746 (1995-12-01), None
patent: WO9615794 (1996-05-01), None
patent: WO9619458 (1996-06-01), None
patent: WO9619997 (1996-07-01), None
patent: WO9713767 (1997-04-01), None
patent: WO9749407 (1997-12-01), None
patent: WO9814436 (1998-04-01), None
patent: WO9827059 (1998-06-01), None
patent: WO9855116 (1998-12-01), None
patent: WO9910325 (1999-03-01), None
patent: WO9911264 (1999-03-01), None
patent: WO9915500 (1999-04-01), None
patent: WO9944608 (1999-09-01), None
Clemence et al., “New 4-(amino-alkoxy-phenyl-methyl)1H-indole Derivatives”, Abstract of Russian Patent No. 2067576 (Oct. 10, 1996).
Hewawasam et al., “New 3-Phenyl Oxindole Derivatives”, Abstract of Russian Patent Application No. 96111002 (Apr. 27, 2001).
Ehrgott et al., “New 1,3-Disubstituted-2-Oxo-Indole Derivatives”, Abstract of Russian Patent No. 2073671 (Feb. 20, 1997).
Buzzetti et al., “3-(Bicyclylmethylene)oxindole Antiangiogenic Agents”, Abstract of US Patent No. 5,576,300 (Nov. 19, 1996).
Fensome et al., “New Progesterone Receptor Antagonists: 3,3-Disubstituted-5-aryloxindoles”, Bio. & Med. Chem. Lett., 12:3487-3490 (2002).
Fensome et al., “Novel 5-Aryl-1,3-Dihydro-Indole-2-Thiones: Potent, Orally Active Progesterone Receptor Agonists”, Bio. & Med. Chem. Lett. 13:1317-1320 (2003).
R. Evans, “The Steroid and Thyroid Hormone Receptor Superfamily”, Science, 240:889 (May 13, 1988).
A. Ulmann et al, “Clinical Uses of Mifepristone (MFP)”, Ann. N.Y. Acad. Sci., 261:248 (Jun. 12, 1995).
R. Kekkonen et al, “Sequential Regiment of the Antiprogesterone RU486 and Synthetic Progestin for Contraception”, Fertility and Sterility, 60(4):610 (Oct., 1993).
K. Horwitz et al, “Progestin, Progesterone Receptors, and Breast Cancer”, Horm. Cancer, publisher: Birkhaeuser, Boston, Mass., ed. Vedeckis, pp. 283-306 (1996) (abstract only).
A. Murphy et al, “Regression of Uterine Leiomyomata in Response to the Antiprogesterone RU486”, J. Clin. Endo. Metab., 76(2):513 (Feb., 1993).
L. Kettel et al, “Endocrine Responses to Long-Term Administration of the Antiprogesterone RU486 in Patients with Pelvic Endometriosis”, Fertility and Sterility, 56(3):402 (Sep., 1991).
H. Michna et al, “Differentiation Therapy with Progesterone Antagonists”, Ann. N.Y. Acad. Sci., 761:224 (Jun., 1995).
L. Zhi et al, “5-Aryl-1,2-Dihydrochromeno[3,4-f]quinolines: A Novel Class of Nonsteroidal Human Progesterone Receptor Agonists”, J. Med. Chem., 41(3):291 (Oct. 22, 1998).
D. Combs et al, “Nonsteroidal Progesterone Receptor Ligands. 2. High-Affinity Ligands with Selectivity for Bone Cell Progesterone Receptors”, J. Med. Chem., 38:4880 (Dec. 8, 1995).
K. Perlman et al, “20-Oxopregnacalciferols: Vitamin D Compounds that Bind the Progesterone Receptor”, Tet. Letters, 35(15)2295 (1994).
L. Hamann et al, “Synthesis and Biological Activity of Novel Nonsteroidal Progesterone Receptor Antagonists”, Ann. N.Y. Acad. Sci., 761:383 (Jun. 12, 1995).
R. Chen et al, “Synthesis and SAR of a Novel Series of Spirobenzothlzaepine Derivatives with Antiprogestin Activity”, POI-37, 16thInt. Cong. Het. Chem., Montana (1997).
B. Narr et al, “Preparation, Testing, and Formulation of Imidazobenzoxazines as Cardiotonics”, Chemical Abstracts, 109:22973 (1988).
R. Hartmann et al, “Effects of Brofoxine, A New Anxiolytic on Experimentally Induced Conflict in Rats”, Proc. West. Pharmacol. Soc., 21:51-55 (1978).
B. Singh et al, “Novel cAMP PDE III Inhibitor” Imidazo[4,5-b]pyridin-2(3H)-ones and Thiazolo[4,5-b]pyridin-2(3H)-ones a
Edwards James P.
Fensome Andrew
Jones Todd K.
Koko Marci C.
Melenski Edward G.
Howson and Howson
Ligand Pharmaceuticals Inc.
Solola Taofiq
Wyeth
LandOfFree
Thio-oxindole derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thio-oxindole derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thio-oxindole derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3411102